DB107-RRV

Phase 2Small molecule

AAshish Shah

DB107-RRV is one of 17 small molecule programs targeting Anaplastic Astrocytoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Anaplastic AstrocytomaRecruiting

Anaplastic AstrocytomaPhase 2

Recruiting

Competition

Competitive Landscape

16 competitors in Anaplastic Astrocytoma

#DrugCompanyPhaseTrials

Gilenya

Cialis

Istodax

Actos

Ixempra

Valtrex

GGlaxo Dba Glaxosmithkline

Approved

—7

Revlimid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Paraplatin

Temodar

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

7 10

Tafinlar

Novartis

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2034

Phase 2Recruiting

Anaplastic Astrocytoma

NCT06264388

Clinical

Trials by Indication[1]

Anaplastic Astrocytoma1 trial

DB107-Retroviral Replicating Vector (RRV) Combined With DB107-Flucytosine (FC) in Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma

Recruiting·AAshish Shah·Phase 2·NCT06264388·33 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for DB107-RRV. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DB107-RRV compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DB107-RRV. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ashish Shah company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AAshish Shah

DB107-RRV

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2034

Trials by Indication[1]

Anaplastic Astrocytoma1 trial

References

Drug Info

Quick Facts

Related News